Glenmark, which recently joined hands with the Ficci Aditya Birla CSR Centre for Excellence to combat child malnutrition, feels there is a need for innovative solution to counter the crisis. “We need to introduce innovative ways to disseminate information on right and healthy practices among rural masses. Time has now come to employ practical solutions rather than theoretical ones to ensure that our children remain healthy,” says Cheryl Pinto, director corporate affairs, Glenmark. While the company has no plans to foray into neutraceutical segment, it says it is committed to work towards the social cause.
Similarly, Biocon, which is currently largely focused on oncology and preventive care-related CSR, is now exploring new areas such as child malnourishment to work on. “When we work on ground, we see there is a need to spread awareness and work in this area. Child malnourishment is a major problematic area in our country and needs to be addressed,” says Rani Desai, head-Biocon Foundation.
Unlike various developing countries, in India, child malnutrition is a bigger problem than infant mortality. According to experts, while India has been able to save children from dying as infants, most of these children survive as unhealthy and disabled population because of malnorishment, which is an even dangerous situation.
While the industry is of the view that resources should be used adequately by the government to cater to rural areas and address the problem, the civil society insists the problem of malnourishment be solved by the government alone as a public service.
Alex George, director, Action Aid India, insists marketisation of the campaign against malnutrition be barred as that results in introduction of unnecessary products in the market.
Some also feel the government needs to address the problem with proper regulations and checks in place. Vandana Prasad, member, National Commission for Protection of Child Rights, says there is a need for a systematic implementation of government programmes to address malnutrition. As a market, the segment is growing rapidly. Currently, the neutraceutical market is pegged at around Rs 1,000 crore with major players from both FMCG and pharma sectors entering the space.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)